Longevity Startup Raises $435M for Liver Aging Trial

Scientists are one step closer to making aging a treatable condition, not an inevitable decline.

NewLimit, a South San Francisco biotech startup, announced Tuesday it raised a massive $435 million to launch its first human clinical trial. The company will test a medicine designed to rejuvenate aging liver cells, marking a major milestone in the emerging field of longevity science.

The Series C funding round was led by Founders Fund, with participation from Thrive Capital, Lilly Ventures, and prominent tech investors. The investment brings NewLimit's valuation to $3.1 billion, just five years after its founding in 2021.

NewLimit was created by an unconventional team of founders. Coinbase CEO Brian Armstrong, former Google Ventures partner Blake Byers, and stem cell biologist Jacob Kimmel joined forces with a bold vision: to develop medicines that don't just treat diseases, but address aging itself at the cellular level.

The company has moved remarkably fast for biotech standards. This is their third major funding announcement in just 13 months, following a $130 million Series B in May 2025 and an additional $45 million last October.

The liver trial represents a strategic first target. The liver is one of the body's most regenerative organs, making it an ideal testing ground for anti-aging therapies. Success here could pave the way for treatments targeting other organs and age-related conditions.

The Ripple Effect

This isn't just about helping people live longer. It's about extending healthspan, the years we live free from chronic disease and disability.

Age-related conditions like diabetes, heart disease, and dementia affect millions and cost healthcare systems trillions annually. If NewLimit's approach works, it could shift medicine from managing decline to preventing it entirely.

The pharmaceutical giant Eli Lilly's venture arm backing this effort signals growing mainstream acceptance of longevity medicine. What once seemed like science fiction is becoming serious science, with serious money behind it.

Other biotech companies are racing to crack the aging code, but NewLimit's rapid progress and substantial funding give it a strong advantage. The company's interdisciplinary approach, combining Silicon Valley innovation with rigorous biological research, represents a new model for tackling humanity's oldest challenge.

The clinical trial timeline hasn't been announced yet, but the funding means NewLimit can move forward without delay.

A future where aging doesn't mean inevitable decline is moving from possibility to reality.